Accelr8 Stock Climbs 13 Percent on New Patent Win | GenomeWeb
NEW YORK (GenomeWeb News) – Shares in Accelr8 were up 13.17 percent, or $.27, at $2.32 in mid-afternoon trading after the company said it won a US patent that covers devices that use its OptiChem surface chemistry, including those for patient specimen collection and analytical products.
 
Accel8 said U.S. Patent 7,067,194 also covers coating variations not specifically included in prior patents.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Harold Varmus, a former NIH director, says that proposed reductions to the agency's budget are worrisome.

The Genome 10K project is to sequence about 10,000 vertebrate genomes, including ones of endangered species, Digital Trends reports.

The new Coalition to Save NIH Funding aims to educate lawmakers and the public on the significance of biomedical research.

In PLOS this week: analysis of viral sequences from human blood samples, gut microbiomes of heart failure patients, and more.